MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
Rhea-AI Summary
MBX Biosciences (Nasdaq: MBX) announced that Kent Hawryluk, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
Format includes a company presentation and 1x1 meetings at 3:45 p.m. PT / 6:45 p.m. ET in San Francisco. A live webcast will be available via the company’s investor events page, with a replay posted approximately two hours after the events and archived for about 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – MBX
In the Dec 15 session, MBX declined 4.96%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 18 | Conference appearance | Neutral | +2.9% | Piper Sandler healthcare conference participation with webcast access for investors. |
| Nov 06 | Earnings & pipeline | Positive | +9.7% | Positive Phase 2 data, cash of $391.7M and funding runway into 2029. |
| Oct 20 | Multiple conferences | Neutral | +7.6% | Participation in four November investor conferences with webcast access. |
| Sep 29 | Conference appearance | Neutral | +2.5% | Stifel virtual cardiometabolic forum fireside chat and webcast. |
| Sep 24 | Equity offering | Negative | +6.0% | Pricing of upsized public offering of 11.1M shares at $18.00 per share. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent MBX headlines—earnings, financings, and conference participation—were typically followed by positive 24-hour price moves, with only the upsized public offering showing a positive reaction to an equity issuance.
Over the last several months, MBX reported positive Phase 2 canvuparatide data, strengthened its balance sheet via an upsized offering, and detailed a cash position of $391.7M as of Sept 30, 2025. The company has been highly visible at multiple investor and healthcare conferences, each announcement coinciding with single‑day gains between roughly 2–8%. Today’s J.P. Morgan Healthcare Conference appearance continues this pattern of active investor engagement following a period of clinical and financing milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco being held on January 12-15, 2026.
44th Annual J.P. Morgan Healthcare Conference
Date: Tuesday, January 13, 2026
Format: Company presentation and 1x1 meetings
Time: 3:45 p.m. PT/ 6:45 p.m. ET
Location: San Francisco, California
The live webcast can be accessed in the events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
Media Contact:
Cassidy McClain
Inizio Evoke Comms
cassidy.mcclain@inizioevoke.com
(619) 694-6291
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
